Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 6/20 | 0.45 |
| ▸ | NAMPT | P43490 | 3/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486031 | 0.90 | MAP4K4 (0.40) | ATRKITKCNH2EPHX2CHRNA7 | |
| SCHEMBL3050002 | 0.89 | NAMPT (0.47) | ATRNAMPTKITADRA2AADRA2B | |
| SCHEMBL3054387 | 0.89 | NAMPT (0.47) | ATRNAMPTKITADRA2AADRA2B | |
| SCHEMBL3044891 | 0.88 | NAMPT (0.48) | ATRNAMPTABL1BCRADRA2A | |
| SCHEMBL3044903 | 0.88 | NAMPT (0.47) | ATRNAMPTABL1BCRADRA2A | |
| SCHEMBL3046413 | 0.88 | NAMPT (0.46) | ATRNAMPTKITADRA2AADRA2B | |
| SCHEMBL3053504 | 0.88 | NAMPT (0.49) | NAMPTABL1BCRADRA2AADRA2B | |
| SCHEMBL3051338 | 0.88 | NAMPT (0.48) | ATRNAMPTADRA2AADRA2BKCNH2 | |
| SCHEMBL3053585 | 0.86 | NAMPT (0.47) | ATRNAMPTADRA2AADRA2BKCNH2 | |
| SCHEMBL3053090 | 0.86 | NAMPT (0.47) | ATRNAMPTADRA2AADRA2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | claimed |
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222319-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | NNT, NAMPT, NQO1 | ATR 3443/4885NAMPT 2/4885KIT 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.